KINATHERA is a preclinical biotech on a mission to develop unique series of newly patented, orally delivered small chemical molecules to treat patients suffering from immuno-inflammatory disorders. Selective inhibition of our most advanced target, simultaneously:
1, blocks intracellular cascade of the ICOS receptor which control maturation of the humoral response and
2, inhibits type 1 interferon production, a master regulator of BAFF expression and demonstrated component of auto-immune diseases. Activity of Kinathera’s compound on two key immune paths promises enhanced control of hyperactive immune reactions in auto immune or GvHD indications.